Effects of Dapagliflozin in Chronic Kidney Disease

Dapagliflozin in Patients with Chronic Kidney Disease

Participants in our trial also had a high risk of hospitalization for heart failure or death from cardiovascular causes. The lower risk of ...

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without ...

Dapagliflozin reduced the risk of kidney and cardiovascular events in patients with chronic kidney disease and albuminuria with and without type 2 diabetes.

Dapagliflozin in Patients with Chronic Kidney Disease - PubMed

Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained ...

The long-term effects of dapagliflozin in chronic kidney disease

The study objective was therefore to extrapolate the outcome-based clinical benefits of treatment with dapagliflozin in patients with CKD via a time-to-event ...

Dapagliflozin for Chronic Kidney Disease - NCBI Bookshelf

The benefits of dapagliflozin in treating the dual epidemic of T2D with CV comorbidities have been recognized, and more recently, dapagliflozin has been ...

Dapagliflozin And Prevention of Adverse outcomes in Chronic ...

The DAPA-CKD trial showed that dapagliflozin results in salutary effects on renal function and mortality among patients with CKD, irrespective of DM status.

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

The sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in patients with CKD with or ...

Effect of dapagliflozin on the rate of decline in kidney function in ...

Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial.

Effects of dapagliflozin on major adverse kidney and cardiovascular ...

Dapagliflozin reduces the risk of kidney failure and heart failure in patients with chronic kidney disease. We aimed to investigate the effects of ...

Effects of Dapagliflozin in Patients With Kidney Disease, With and ...

Dapagliflozin improves both HF and kidney outcomes in CKD patients, with or without type 2 diabetes, independently of history of HF.

Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic ...

Dapagliflozin reduced the risk of kidney failure, death from cardiovascular causes or hospitalization for heart failure, and prolonged survival in people with ...

Effects of Dapagliflozin in Chronic Kidney Disease Across the ...

In summary, dapagliflozin reduced the risks of mortality, cardiovascular events, and CKD progression in women and men, and among patients across ...

Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney ...

Similar to the primary composite outcome, dapagliflozin reduced the incidence of the kidney composite endpoint, cardiovascular composite endpoint, and all-cause ...

Effects of dapagliflozin on major adverse kidney and cardiovascular ...

Background. Dapagliflozin reduces the risk of kidney failure and heart failure in patients with chronic kidney disease. We aimed to investigate the effects of ...

Long-term benefits of dapagliflozin on renal outcomes of type 2 ...

Approximately 1 in 3 adults with diabetes has chronic kidney disease (CKD). Diabetes accelerates the progression to end-stage kidney disease (ESKD), which ...

New PBS listing: Dapagliflozin for chronic kidney disease

It is responsible for resorption of approximately 90% of filtered glucose in the kidneys. Inhibition of SGLT2 leads to multiple effects, ...

Chronic Kidney Disease | FARXIGA® (dapagliflozin) 5 mg & 10 mg ...

FARXIGA is the ONLY SGLT2i proven to significantly reduce the risk of the composite of CV death or hospitalization for HF in patients with CKD, with or without ...

A pre-specified analysis of the DAPA-CKD trial demonstrates the ...

In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease trial, dapagliflozin reduced the risk of kidney failure and ...

Effectiveness and Safety of Dapagliflozin for Black and White ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been demonstrated to lower risks of progressive kidney disease, cardiovascular events, ...

Effects of Dapagliflozin in Patients With Chronic Kidney Disease

Dapagliflozin reduced the risk of adverse kidney outcomes, hospitalisation for HF or cardiovascular death, and prolonged survival in people with CKD.